The 2012 Dup15q Scientific Meeting was held on August 9-10, 2012 at Boston Children's Hospital. The two-day conference was attended by more than sixty scientists, researchers and professionals interested in Duplication 15q Syndrome. It was sponsored in part by Austism Speaks and Lineagen.

Below are the speakers and presentation titles, as well as links to the video of each, if they are available.

Brenda Finucane - VIEW VIDEOIntroduction and Familial Reports

Genetics I: Molecular Genetics
N. Carolyn SchanenInto to 15q duplications
Stormy Chamberlain - VIEW VIDEO        Human induced pluripotent stem cell models of 15q duplications syndrome
Janine LaSalle- VIEW VIDEO     Dup15q brain expression, methylation, and environmental analyses
Ian King - VIEW VIDEO       Unsilencing of paternal Ube3a by topoisomerase inhibitors
Caleigh Mandel-Brehm Genetic rescue of behavioral deficits in a mouse model of Angelman Syndrome

Genetics II: Animal Models and Translational Research
Randall Carpenter- VIEW SLIDES   Scientific Discoveries Allow Development of Targeted Therapeutics for Individuals with
  Austism Spectrum Disorders
Matt AndersonIdic15: Where in the cell is that drug target?
Robert Nicholls      New animal models to study human 15q11-q13 syndromes
Scott Dindot   Genomic Imprinting of Ube3a in the Brain
Lawrence Reiter - VIEW SLIDES   From flies to bedside: identification of UBE3A targets that may influence the phenotypes
  in maternal duplications and deletions of 15q.

Kadi Luchsinger - VIEW SLIDES     Registry Update

Clinical Insights I: Autism, language, learning, and behavior
Jerzy Weigel  Clinicopathological stratification of diopathic autism and autism assocated with duplications
Lawrence Reiter - VIEW VIDEO (VIEW SLIDES)
      Characterization of the interstitial duplication 15q syndrome
Andrew Papanicolaou - VIEW VIDEO    Detection of Austism through resting and task-related neuronal networks
        Psychopharmacology of Autism Spectrum Disorders

Clinical Insights II: Epilepsy, sleep and SUDEP
Ron Thibert - VIEW VIDEO      Clinical data from the first year of the Dup15q Center and brief seizure study update
Kiran Maski  Heart reponse to arousals from sleep in 15dup children and potential contribution to sudden
Daniel Friedman  Identifying risk factors for SUDEP in patients with Dup15q


2012 Dup15q Scientific Meeting
Dup15q Alliance, P.O. Box 674, Fayetteville, NY 13066  USA
Policy Regarding Use of Dup15q Alliance Trademarks

The trademarks, logos, and service marks (“Marks”) displayed on this website, and related websites belonging to Dup15q Alliance, including the Dup15q Alliance logo, among others, are trademarks of the Dup15q Alliance, are the property of Dup15q Alliance, and are protected. Their uses are restricted to those programs and events sponsored by Dup15q Alliance, and Dup15q Alliance trademarks may not be used for personal financial gain. Use of the Marks is prohibited without the express written consent of Dup15q Alliance. Nothing contained on the Site should be construed as granting, by implication, estoppel, or otherwise, any license or right to use the Marks without the express written consent of Dup15q Alliance.

At times, Dup15q Alliance may grant limited-use licensing agreements to those individuals or groups who wish to help further the mission of Dup15q Alliance. Solely at the discretion of Dup15q Alliance, limited permission for use of Dup15q Alliance’s Marks may be granted for those projects which provide a substantial benefit to Dup15q Alliance or the chromosome 15q duplication syndrome community in general. For consideration, please submit, in writing, a letter of intent, which details how the Dup15q Alliance’s Marks will be used, the length of time they will be used, and the benefit of the project to Dup15q Alliance or the chromosome 15q duplication syndrome community to at least 45 days prior to launch.
Letters of intent may also be sent to: Dup15q Alliance, PO Box 674, Fayetteville, NY 13066, or send an e-mail to